Unlocking LOC400464: A Potent Drug Target for Ubiquitin Conjugating Enzyme E2 Q2 Pseudogene

Unlocking LOC400464: A Potent Drug Target for Ubiquitin Conjugating Enzyme E2 Q2 Pseudogene

Unlocking the Potential of LOC400464: A Potent Drug Target and Biomarker for Ubiquitin Conjugating Enzyme E2 Q2 Pseudogene

The ubiquitin system is a complex protein regulatory network involved in various cellular processes, including DNA damage repair, protein degradation, and cell signaling. Enzyme E2 ( Ubiquitin Conjugating Enzyme E2 ) is a key player in this system, catalyzing the formation of ubiquitin chains on target proteins. The pseudogene, LOC400464, has been identified as a potential drug target or biomarker due to its unique structure and function. In this article, we will explore the molecular mechanism of LOC400464 and its potential applications in drug development.

Molecular Mechanism of LOC400464

LOC400464 is a single-chain protein with 111 amino acid residues. It belongs to the Ubiquitin-Proteasome System (UPS) and is localized to the endoplasmic reticulum (ER) and nuclear envelope (NE). LOC400464 functions as an enzyme, catalyzing the formation of ubiquitin chains on target proteins.

The active site of LOC400464 is located at its N-terminus, where it interacts with the substrate protein. The substrate protein is held in a specific orientation, allowing the enzyme to create a specific conformation that is necessary for ubiquitin chain formation. The catalytic cycle is completed by a His-212 substitution, which is located in the middle of the active site.

LOC400464 has been shown to have a unique stability property. It has a Mr of 18,347, which is higher than the typical Mr of other Ubiquitin-conjugating enzymes. This stability is important for LOC400464 to function as an enzyme and for it to be a potential drug target.

Potential Applications of LOC400464

The discovery of LOC400464 as a potential drug target or biomarker has significant implications for the development of new treatments. If LOC400464 is successfully targeted, it could lead to the development of new drugs that target this protein and improve the treatment of various diseases.

One potential application of LOC400464 is in the treatment of cancer. LOC400464 has been shown to be involved in the regulation of cell cycle progression and has been associated with the development of various cancers. Targeting LOC400464 could lead to the development of new cancer treatments that inhibit its activity.

Another potential application of LOC400464 is in the treatment of neurodegenerative diseases. LOC400464 has been shown to be involved in the regulation of protein degradation and has been linked to the development of neurodegenerative diseases. Targeting LOC400464 could lead to the development of new treatments that slow down or reverse the progression of these diseases.

Another potential application of LOC400464 is in the treatment of genetic disorders. LOC400464 has been shown to be involved in the regulation of DNA damage repair and has been associated with a number of genetic disorders. Targeting LOC400464 could lead to the development of new treatments that treat these disorders.

Conclusion

LOC400464 is a unique protein with a Mr of 18,347 that belongs to the Ubiquitin-Proteasome System. It has been shown to have a unique stability property and to be involved in the regulation of cell cycle progression, protein degradation, and DNA damage repair. due to its unique structure and function, LOC400464 has the potential to be a drug target or biomarker, which could lead to the development of new treatments for various diseases.

Protein Name: Ubiquitin Conjugating Enzyme E2 Q2 Pseudogene

The "LOC400464 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC400464 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC400499 | LOC400541 | LOC400576 | LOC400622 | LOC400627 | LOC400682 | LOC400692 | LOC400706 | LOC400707 | LOC400768 | LOC400940 | LOC401021 | LOC401052 | LOC401127 | LOC401261 | LOC401312 | LOC401324 | LOC401357 | LOC401410 | LOC401478 | LOC401480 | LOC401557 | LOC401589 | LOC401703 | LOC401913 | LOC402221 | LOC403312 | LOC407835 | LOC414300 | LOC439933 | LOC440157 | LOC440300 | LOC440311 | LOC440313 | LOC440700 | LOC440864 | LOC440895 | LOC440910 | LOC440982 | LOC441052 | LOC441081 | LOC441087 | LOC441179 | LOC441228 | LOC441239 | LOC441455 | LOC441666 | LOC441722 | LOC441956 | LOC442028 | LOC442497 | LOC497256 | LOC541473 | LOC550113 | LOC553139 | LOC554206 | LOC574080 | LOC606724 | LOC613266 | LOC642131 | LOC642361 | LOC642422 | LOC642502 | LOC642590 | LOC642677 | LOC642730 | LOC642846 | LOC642947 | LOC643201 | LOC643339 | LOC643406 | LOC643441 | LOC643454 | LOC643763 | LOC643855 | LOC643923 | LOC644006 | LOC644083 | LOC644086 | LOC644189 | LOC644215 | LOC644277 | LOC644525 | LOC644584 | LOC644634 | LOC644656 | LOC644662 | LOC644669 | LOC644893 | LOC644936 | LOC645086 | LOC645181 | LOC645188 | LOC645266 | LOC645468 | LOC645503 | LOC645967 | LOC646044 | LOC646214 | LOC646358